IN THE NEWS: FDA Approves New Drugs for Liver Infections
It's a great opportunity for us to start the year announcing an outstanding release of two new drugs for the treatment of a rising chronic viral liver infection, such as Hepatitis C. FDA has released just recently Simeprevir (Olysio) and Sofosbuvir (Sovaldi) for the treatment of chronic Hepatitis C as a component of a combination antiviral treatment regimen.
Simeprevir (Olysio) is a NS3/4A protease inhibitor approved by FDA for treatment of HVC infection, genotype 1, in combination with PEG Interferon and Ribaviran, with response rates of 60 (prior partial and null responders) to 80% (prior relapsers and patients without prior treatment exposure).
Sofosbuvir (Sovaldi) is a nucleotide analog NS5B polymerase inhibitor, with significant efficacy (response rates of 80-90%) established in subjects with HCV genotype 1,2,3, or 4 infection, including those patients
NEWS: New Liver Drugs (Continued)
with liver cancer, awaiting liver transplantation and those with HCV/HIV coinfection. Another promising advantage for patients is shorter periods of treatment, from 12-24 weeks in total.
These new drug releases will definitely change the efficacy and compliance of treatment regimen of our patients with promising rates of virus eradication. We invite you to contact us for initial evaluation and discussion of this growing and concerning chronic liver disorder.
If you would like to schedule an appointment to meet with one of our physicians or to discuss these new drug treatments, please contact our office at (239) 593-6201 or send an email with the subject “Liver Infection Treatment” to firstname.lastname@example.org.
Why Choose Us?